Biogen discloses PML cases, one death in Tysabri patients

Four more patients taking Biogen Idec's multiple sclerosis drug Tysabri have developed the serious brain infection known as progressive multifocal leukoencephalopathy (PML), and one of them died, according to the company's monthly update. That brought the total number of confirmed cases as of Dec. 2 to 79, with 16 deaths. Report

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.